skip to primary navigationskip to content


PsynovaA key component of the CCNR has been the establishment of a spin-out company, Psynova Neurotech Ltd, to act as a seamless route to commercialise its research. Psynova Neurotech Ltd provides a vehicle to exchange results, resources and people between the academic Centre and the company by exploiting the results of the work of the Centre, and sustaining the research programme via joint grants and contracts.


Psynova Neurotech Ltd (SME)

In 2011 Psynova was acquired and IP was transferred to Myriad Genetics. In 2013 the company was returned to Professor Bahn and is currently being restructured to provide services to collaborating academic and commercial institutions in relation to multiplexed immunological assays and Selective Reaction Monitoring Assay application and to undertake grant funded research.

At present, 5 members of the Bahn laboratory are seconded from Psynova to the Bahn laboratory where Dr Sureyya Ozcan is overlooking the research activities as Director of Research.


Psynova Services

Psynova Neurotech Ltd is focusing on the biomarker discovery program in the field of neuropsychiatric diseases. In line with our research programme in Psynova we have developed a comprehensive and cost-effective multiplexed platform called Neuropsych, which is currently offered to our clients under commercial terms. The neuropsych platform targets numerous serum and plasma proteins that have been implicated in psychiatric disorders including Schizophrenia, Major Depressive Disorder and Bipolar Disease. Our targeted approach and analyte selection is based on over 20 years of experience in the field of biomarker discovery evidenced by more than 150 scientific publications.

The platform consists of two complementary high-throughput approaches, multiplex immunoassay and multiple reaction monitoring (MRM) mass spectrometry. The dual approach allows us to measure analytes quantitatively across a wider concentration range. Both methods were developed not to require pre-fractionation and therefore eliminates this as a potential source of artefactual variability. Also the sample preparation protocol is managed by a robotic instrument in order to minimise human error and increase robustness. The assays have been validated for serum and plasma samples reducing the risk of high percentage of missing data effect. The assays were established for small amounts of sample, with MRM requiring less than 1ul of serum for the analysis of over 50 analytes. The assays can be customised in order to meet specific research requirements of our customers. To our clients we can also offer comprehensive statistical analysis of the acquired data and can help with the study design.


Psynova Team

Prof Sabine Bahn MD PhD MRCPsych

Jason Cooper PhD - Head of Statistics

Sureyya Ozcan PhD - Director of Research

Olia Mikova MD

Jakub Tomasik PhD

Jantine Broek PhD student

Geertje van Rees PhD student